Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws

Head and Neck

Volumn 34, Issue 2, 2012, Pages 194-200

  Wutzl, Arno ^a   Pohl, Sebastian ^a   Sulzbacher, Irene ^a   Seemann, Rudolf ^a   Lauer, Günter ^a   Ewers, Rolf ^a   Drach, Johannes ^a   Klug, Clemens ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bisphosphonates; jaws; necrosis; outcome; surgery

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BISPHOSPHONIC ACID RELATED OSTEONECROSIS OF THE JAW; CLINICAL ARTICLE; DENTAL PROCEDURE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; MALE; MULTIPLE MYELOMA; NEOPLASM; OSTEOPOROSIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPOROSIS; RADIOGRAPHY, PANORAMIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855693336     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21708     Document Type: Article

References (37)

1. Marx RE,. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1118 [Letter].
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S,. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534. (Pubitemid 38542516)
3. Migliorati CA,. Bisphosphanates and oral cavity cancer avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
4. Wang J, Goodger NM, Pogrel MA,. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 6: 1104-1107. (Pubitemid 37064708)
5. Marx RE, Sawatari Y, Fortin M, Broumand V,. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575. (Pubitemid 41525412)
6. Migliorati CA, Schubert MM, Peterson DE, Seneda LM,. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93. (Pubitemid 40847755)
7. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006; 42: 327-329 [Letter]. (Pubitemid 43246766)
8. Woo SB, Hellstein JW, Kalmar JR,. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761. (Pubitemid 46780635)
9. Woo SB, Hande K, Richardson PG,. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 2005; 353: 99-102 [Letter].
10. Wutzl A, Eisenmenger G, Hoffmann M, et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 2006; 118: 473-478. (Pubitemid 44407466)
11. Hellstein JW, Marek CL,. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005; 63: 682-689. (Pubitemid 40602707)
12. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.
13. Dannemann C, Grätz KW, Zwahlen RA,. Bisphosphonate-induced osteonecrosis of the jaws-a guide to diagnosis, therapy and prevention of BON in dental practice. Schweiz Monatsschr Zahnmed 2008; 118: 113-123.
14. Allen MR, Burr DB,. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67: 61-70.
15. Durie BG, Katz M, Crowley J,. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
16. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587. (Pubitemid 46211499)
17. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-120.
18. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945-952. (Pubitemid 46638849)
19. Ruggiero SL, Fantasia J, Carlson E,. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-441. (Pubitemid 44403162)
20. Kyrgidis A, Vahtsevanos K,. Risk factors for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 2553-2554.
21. Wessel JH, Dodson TB, Zavras AI,. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66: 625-631. (Pubitemid 351381804)
22. Jadu F, Lee L, Pharoah M, Reece D, Wang L,. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015-2019. (Pubitemid 350286242)
23. Sarasquete ME, González M, San Miguel JF, García-Sanz R,. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009; 15: 382-387.
24. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB,. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 1658-1668. (Pubitemid 41810027)
25. Melo MD, Obeid G,. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 2005; 136: 1675-1681. (Pubitemid 41810029)
26. Wutzl A, Biedermann E, Wanschitz F, et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2008; 30: 1224-1230.
27. Abu-Id MH, Warnke PH, Gottschalk J, et al. "Bis-phossy jaws": high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008; 36: 95-103.
28. Kyrgidis A, Koloutsos G, Vahtsevanos K,. Treatment protocols of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2009; 31: 1112-1113.
29. Tirelli G, Biasotto M, Chiandussi S, et al. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck 2009; 31: 1249-1254.
30. Marx RE, Cillo JE Jr, Ulloa JJ,. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410. (Pubitemid 350100982)
31. Dodson TB,. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 44-52.
32. Dimitrakopoulos I, Magopoulos C, Karakasis D,. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006; 35: 588-593. (Pubitemid 43863136)
33. Lee CY, Suzuki JB,. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: Biological concepts with a review of the literature. Implant Dent 2009; 18: 492-500.
34. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356-5362.
35. Aragon-Ching JB, Dahut WL,. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist 2008; 13: 1314 [Letter].
36. Bilezikian JP, Raisz LG, Martin TJ,. Principles of bone biology. Biochemical markers of bone metabolism. San Diego, CA: Elsevier; 2008. pp 285-1881.
37. Lee CY, Suzuki JB,. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study. Implant Dent 2010; 19: 29-38.